CD274 and cancer: Pembrolizumab, nivolumab, and cemiplimab, by blocking the PD-1/PD-L1 axis, reduce glucose uptake by cancer cells, leading to an increment of TME glucose concentration that is necessary for CAR-T cell activation (Xu et al., 2019).